Premium
Safety and efficacy of long‐acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6‐month open‐label trial in Asian patients
Author(s) -
Verma Swapna,
Subramaniam Mythily,
Abdin Edimansyah,
Sim Kang,
Su Alex,
Lee Nelson,
Chong Siow Ann
Publication year - 2010
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.1104
Subject(s) - risperidone , medicine , positive and negative syndrome scale , schizophrenia (object oriented programming) , clinical global impression , antipsychotic , repeated measures design , analysis of variance , gastroenterology , psychiatry , psychosis , placebo , statistics , alternative medicine , mathematics , pathology
The study aimed to evaluate the efficacy of long‐acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders. Twenty‐five patients enrolled in this 6‐month open labelled study. They were switched from their current antipsychotic to LAR without a prior oral risperidone run‐in phase. Efficacy was assessed by the positive and negative syndrome scale (PANSS) and clinical global impression (CGI) scales. Extra‐pyramidal side effects (EPSE) was assessed using the Simpson Angus Scale (SAS), and weight and plasma levels of fasting blood glucose, lipids and prolactin were measured. Baseline and last visits differences were tested by paired t ‐test and Wilcoxon signed‐rank test; ratings measured over time were analysed using repeated measures ANOVA. Participants' mean age was 30.3 (±6.6) years. Principal reason for switching to LAR was non‐compliance (40.0%). Thirteen (52%) patients completed the trial. Over 6 months, there were significant reductions in total PANSS ( p = 0.008) and CGI ( p = 0.001) scores. There were significant increases in weight ( p < 0.001), levels of plasma cholesterol and fasting glucose. LAR was effective in improving symptom severity within the first month of starting treatment. However, significant increases in weight and plasma levels of fasting glucose and cholesterol raise concern about metabolic side effects. Copyright © 2010 John Wiley & Sons, Ltd.